After this, DCs migrate to tumor-draining lymph nodes where they induce the differentiation and activation of naïve TAA-specific CD8+ and CD4+ T cells, via the productive engagement of T cell receptors (TCR) by major histocompatibility class I (pMHC-I) or class II (pMHC-II)-antigen peptide complexes, respectively, in conjunction with the recognition of appropriate signals sensed by T cells during the establishment of an immunological synapse [3]. Here, CD8A is linked to neoplasm.